<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1720">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05138770</url>
  </required_header>
  <id_info>
    <org_study_id>VC005-101</org_study_id>
    <nct_id>NCT05138770</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics Clinical Study of VC005 Tablets in Healthy Subjects</brief_title>
  <official_title>Randomized, Double-blind, Dose-escalation, Placebo-controlled Single Administration Phase Ia Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics, Pharmacodynamics and Food Effects of VC005 Tablets in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu vcare pharmaceutical technology co., LTD</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu vcare pharmaceutical technology co., LTD</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial consists of two parts：1. a randomized, double-blind, single-center,&#xD;
      placebo-controlled, dose-escalation PK study; 2. food effects and drug metabolism&#xD;
      transformation study.&#xD;
&#xD;
      The main purpose of this trial is to evaluate the Safety, Tolerance, Pharmacokinetics,&#xD;
      Pharmacodynamics and Food effects of VC005 Tablets in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax）</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak time in plasma(Tmax)</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulative urine excretion rate</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Accumulative fecal excretion rate</measure>
    <time_frame>Day 4</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <arm_group>
    <arm_group_label>VC005 Tablets Dose escalation groups: 1、5、10、25、50、100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VC005 Tablets 1、5、10、25、50、100mg, qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VC005 Tablets Placebo Dose escalation groups: 1、5、10、25、50、100mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>VC005 Tablets Placebo 1、5、10、25、50、100mg, qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VC005 Tablets food effects group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VC005 Tablets, qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VC005 Tablets</intervention_name>
    <description>VC005 Tablets 1、5、10、25、50、100mg single dose</description>
    <arm_group_label>VC005 Tablets Dose escalation groups: 1、5、10、25、50、100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VC005 Tablets Placebo</intervention_name>
    <description>VC005 Tablets Placebo 1、5、10、25、50、100mg single dose</description>
    <arm_group_label>VC005 Tablets Placebo Dose escalation groups: 1、5、10、25、50、100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VC005 Tablets food effects group</intervention_name>
    <description>VC005 Tablets qd per period, for two periods</description>
    <arm_group_label>VC005 Tablets food effects group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female subjects aged 18 to 45 years old，inclusive&#xD;
&#xD;
          2. Male subjects weighing at least 50 kg and female subjects weighing at least 45 kg.&#xD;
             Body mass index (BMI) between 18 and 28 kg/m2, inclusive&#xD;
&#xD;
          3. During the trial and within 3 months after the completion of the trial (the time&#xD;
             should exceed the time required for sperm production), there is no fertility plan, and&#xD;
             is willing to use effective contraceptive measures (non hormonal contraceptive&#xD;
             measures) and there is no sperm donation and egg donation plan&#xD;
&#xD;
          4. Volunteer to participate in the trial and sign an informed consent form&#xD;
&#xD;
          5. Subjects who are able to communicate well with the investigator are willing and able&#xD;
             to comply with all planned visits, treatment plans, laboratory examinations and other&#xD;
             research procedures&#xD;
&#xD;
          6. Physical examination and vital signs are normal or abnormal with no clinical&#xD;
             significance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Suspected to be allergic to the study drug or any component in the study drug, or&#xD;
             allergic constitution&#xD;
&#xD;
          2. abnormal electrocardiogram with clinical significance&#xD;
&#xD;
          3. Those who have evidence of atypical hyperplasia or a history of malignant tumor&#xD;
&#xD;
          4. Suffer from eye diseases, including history of eye surgery or laser surgery (except&#xD;
             laser surgery for myopia)&#xD;
&#xD;
          5. Those who have a history of herpes simplex or herpes zoster 3 months before&#xD;
             administration&#xD;
&#xD;
          6. Have any history or evidence of active tuberculosis (TB) or latent TB infection (TB&#xD;
             enzyme-linked immunospot test (T-SPOT. TB) positive), or have a history of previous&#xD;
             skin TB test or QuantiFERON TB gold in tube test (GIT analysis) positive&#xD;
&#xD;
          7. Known active bacteria, viruses, fungi, parasitic infections or other infections or any&#xD;
             infections that require antibiotic treatment or hospitalization (4 weeks before&#xD;
             screening), or any acute infections within 2 weeks of baseline&#xD;
&#xD;
          8. Those who have participated in clinical trials of any drug or medical device&#xD;
             (including the placebo group) within 3 months before screening&#xD;
&#xD;
          9. Those who have been vaccinated within 2 weeks before administration, or plan to be&#xD;
             vaccinated during the study period&#xD;
&#xD;
         10. Those who are usually anorexia, dieting, or have started a significantly abnormal diet&#xD;
             (such as dieting) within 4 weeks before screening; those who cannot follow a uniform&#xD;
             diet or have difficulty swallowing&#xD;
&#xD;
         11. Those who have undergone any surgeries within 6 months before screening&#xD;
&#xD;
         12. Have used any prescription drugs, over-the-counter drugs, Chinese herbal medicines&#xD;
             within 14 days before screening&#xD;
&#xD;
         13. Those who use any drug that inhibits or induces liver enzyme activity within 28 days&#xD;
             before administration or during the study period&#xD;
&#xD;
         14. Those who were in blood donation within 3 months before screening and donated blood&#xD;
             volume ≥400 mL, or received blood transfusion&#xD;
&#xD;
         15. Those who with dyslipidemia of clinical significance and coronary heart disease&#xD;
&#xD;
         16. Pregnant and lactating females, or females who have a positive pregnancy test&#xD;
&#xD;
         17. Those who have difficulty in blood collection or cannot tolerate venipuncture, and&#xD;
             those who have a history of fainting needles and bleeding&#xD;
&#xD;
         18. Those who smoke ≥ 5 cigarettes per day within 3 months before screening and cannot&#xD;
             stop using any tobacco products from the end of screening to before enrollment and&#xD;
             during the test&#xD;
&#xD;
         19. Those who drink more than 14 units of alcohol per week within 3 months prior to&#xD;
             administration (1 unit of alcohol ≈ 360 mL beer or 45 mL 40% alcohol spirits or 150 mL&#xD;
             wine), or those who cannot abstain from alcohol during the study&#xD;
&#xD;
         20. Those who have taken any food or drink that affects absorption, distribution,&#xD;
             metabolism, and excretion of the drug within 24 hours before administration, such as&#xD;
             food or drink containing caffeine (such as chocolate) and xanthine&#xD;
&#xD;
         21. Those who have consumed pithya , mango, grapefruit, lime, star fruit, or food or&#xD;
             beverage prepared therefrom 2 weeks before the first administration&#xD;
&#xD;
         22. Clinically significant clinical laboratory abnormalities or other clinically&#xD;
             significant diseases (including but not limited to gastrointestinal, renal, hepatic,&#xD;
             neurological, hematological, endocrine, tumor, pulmonary, immunological, psychiatric&#xD;
             or cardiovascular diseases)&#xD;
&#xD;
         23. Those who are positive in urine drug and alcohol test&#xD;
&#xD;
         24. Hepatitis B surface antigen, hepatitis C antibody / hepatitis C core antigen, HIV&#xD;
             antigen / antibody, syphilis antibody positive&#xD;
&#xD;
         25. Subjects with other factors not suitable for the trial considered by the investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>xiaojuan lai</last_name>
    <phone>15358160458</phone>
    <email>lai_xiaojuan@vcarepharmatech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yanhua Ding</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>December 7, 2021</last_update_submitted>
  <last_update_submitted_qc>December 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy subjects</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

